Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

NCT05252390 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT05252390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05252390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 29, 2022
Completion date
July 15, 2024
Enrollment
82 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, breast cancer, breast carcinoma, breast tumor, cancer of breast, cancer of ovary, cancer of pancreas, cancer of prostate, cancer of the breast, cancer of the ovary, cancer of the pancreas, cancer of the prostate, castrate resistant prostate cancer, castration resistant prostatic cancer, castration resistant prostatic neoplasms, ovarian cancer, ovary cancer, ovary neoplasm, pancreas cancer, pancreas neoplasm, pancreatic cancer, prostate cancer, prostate neoplasm, prostatic cancer, triple negative breast cancer, triple negative breast neoplasms, triple-negative breast cancer